Catalent to Discuss how Drug Design Influences Patient Outcomes at PODD
Catalent, a leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, gene therapies and consumer health products, announced it will present at the 9th Partnership Opportunities in Drug Delivery (PODD) annual conference at the Renaissance Boston Waterfront Hotel, Boston on 7-8 October 2019.
On 8 October at 1:20pm, Cornell Stamoran, PhD, Founder and Co-Chair of the Catalent Applied Drug Delivery Institute, will moderate the “Smart Drug Design and Development – from Candidate to Phase 1” panel during the “Formulations” breakout session.
The panel will bring together scientists from industry and academia including Sudhakar Garad, PhD, Global Head of Pharmaceutical and Chemical Profiling, Novartis Institutes for Biomedical Research, Keith Horspool, VP of External Alternative CMC Development, Rebecca Carrier PhD, Professor, Chemical Engineering, Northeastern University and others.
The panellists will explore the key considerations for transitioning a molecule from discovery to clinic and will discuss how every design decision made during this process has the potential to influence patient outcomes.
Dr Stamoran leads Catalent’s strategic planning, market intelligence and government affairs efforts. He has spent nearly 30 years in advanced drug and biologics delivery and outsourcing. Dr Stamoran founded the Catalent Applied Drug Delivery Institute in 2012 to serve as a link between industry and academia, advance education and training in drug delivery in academia and the industry, accelerate adoption of applied drug delivery technologies to develop better treatments, and foster industry collaboration on major issues pertaining to drug development, formulation and delivery.